Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Merck KGAA's Bavencio Fails OS Endpoint In Second-Line Lung Cancer

Executive Summary

The firms still hope to produce positive data in first-line non-small cell lung cancer in 2019, but Bavencio is falling well behind its checkpoint inhibitor competition.
Advertisement

Related Content

Merck KGAA/Pfizer's Anti-PD-L1 Bavencio Loses An Opportunity In Ovarian Cancer
Pfizer/Merck KgAA Move Fast With Bid For Bavencio/Inlyta In Kidney Cancer Market
Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy
AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
Merck Hits IO Bullseye With Keytruda Combo In First-line Lung Cancer
Pfizer/Merck KGAA's Bavencio Gastric Cancer Failure Not As Bad As It Seems
Pfizer's Avelumab Makes Its Debut, In Rare Form Of Skin Cancer

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100411

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel